197 related articles for article (PubMed ID: 31405179)
1. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.
Gomes S; Bosco B; Loureiro JB; Ramos H; Raimundo L; Soares J; Nazareth N; Barcherini V; Domingues L; Oliveira C; Bisio A; Piazza S; Bauer MR; Brás JP; Almeida MI; Gomes C; Reis F; Fersht AR; Inga A; Santos MMM; Saraiva L
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405179
[TBL] [Abstract][Full Text] [Related]
2. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis.
Loureiro JB; Ribeiro R; Nazareth N; Ferreira T; Lopes EA; Gama A; Machuqueiro M; Alves MG; Marabini L; Oliveira PA; Santos MMM; Saraiva L
Pharmacol Res; 2022 Jan; 175():106026. PubMed ID: 34890775
[TBL] [Abstract][Full Text] [Related]
5. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.
Loureiro JB; Raimundo L; Calheiros J; Carvalho C; Barcherini V; Lima NR; Gomes C; Almeida MI; Alves MG; Costa JL; Santos MMM; Saraiva L
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916029
[TBL] [Abstract][Full Text] [Related]
6. SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner.
Ramos H; Calheiros J; Almeida J; Barcherini V; Santos S; Carvalho ATP; Santos MMM; Saraiva L
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963392
[TBL] [Abstract][Full Text] [Related]
7. Triptolide promotes degradation of the unfolded gain-of-function Tp53
Zhou J; Luo J; Li P; Zhou Y; Li P; Wang F; Mallio CA; Rossi G; Jalal AH; Filipovic N; Tian Z; Zhao X
Transl Lung Cancer Res; 2022 May; 11(5):802-816. PubMed ID: 35693277
[TBL] [Abstract][Full Text] [Related]
8. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib Nanomicelles Synergize with Chemotherapy through Inducing Proteasomal Degradation of Mutp53 Proteins.
Yi T; Qian J; Ye Y; Zhang H; Jin X; Wang M; Yang Z; Zhang W; Wen L; Zhang Y
ACS Appl Mater Interfaces; 2023 Jan; 15(1):511-523. PubMed ID: 36578131
[TBL] [Abstract][Full Text] [Related]
10. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.
Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP
Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563
[TBL] [Abstract][Full Text] [Related]
11. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
12. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner.
Cun Y; Dai N; Li M; Xiong C; Zhang Q; Sui J; Qian C; Wang D
Oncol Rep; 2014 Feb; 31(2):901-9. PubMed ID: 24297337
[TBL] [Abstract][Full Text] [Related]
13. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
14. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
15. Structural and Drug Targeting Insights on Mutant p53.
Gomes AS; Ramos H; Inga A; Sousa E; Saraiva L
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283062
[TBL] [Abstract][Full Text] [Related]
16. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
18. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
19. Anticancer efficacy of hirsuteine against colorectal cancer by opposite modulation of wild-type and mutant p53.
Zhang Y; Guo T; Li S; Ren Z; Gao S; Lu H; Ma X; Liu D; Liu Y; Kong D; Qiu Y
Discov Oncol; 2023 May; 14(1):84. PubMed ID: 37256374
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
